Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD

Blood (2015) 126 (23): 2137.

https://doi.org/10.1182/blood.V126.23.2137.2137

Published: 2015

Journal Articles

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Austin G Kulasekararaj, MBBS, MD, Shreyans A Gandhi, MBBS, MD, Lindsay D Mitchell, MBChB, Modupe Elebute, MBChB, MD, Stephen John Richards, PhD, Matthew Cullen, MSc, Louise M Arnold, RN, BSc, Joanna Large, RN, BSc, Alexandra Wood, RN, BSc, Gemma L Brooksbank, RN, BSc, Tracy Downing, Claire McKinley, BSc, Dena Cohen, BSc, MSc, Walter M Gregory, PhD, Judith C. W. Marsh, MD, PhD, Ghulam J. Mufti, MD, Peter Hillmen, MBChB, PhD

Blood (2012) 120 (21): 3472.

https://doi.org/10.1182/blood.V120.21.3472.3472

Published: 2012

Journal Articles

Prospective Phase II Pilot Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline) with Ciclosporin for Patients with Acquired Aplastic Anemia and Matched Pair Analysis with Patients Treated with Horse ATG (Lymphoglobuline) and Ciclosporin: A Study From the EBMT Severe Aplastic Anemia Working Party (RATGAA07)

Judith C Marsh, Gérard Socié, Hubert Schrezenmeier, MD, Andre Tichelli, Antonio M. Risitano, Jakob R. Passweg, MD, Carlo Dufour, MD, Mahmoud Aljurf, MD, Hazza A Al-Zahrani, Rosi Oneto, Philip Sedgwick, Barrois Alain, Shahram Kordasti, Modupe Elebute, Ghulam J. Mufti, MD, Andrea Bacigalupo

Blood (2011) 118 (21): 2408.

https://doi.org/10.1182/blood.V118.21.2408.2408

Published: 2011

Journal Articles

Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,

Jie Jiang, PhD, Austin G Kulasekararaj, Pramila Krishnamurthy, Alexander E Smith, PhD, Syed A Mian, Shreyans Gandhi, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, FRCP, FRCPath, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 3826.

https://doi.org/10.1182/blood.V118.21.3826.3826

Published: 2011

Journal Articles

TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis

Austin G Kulasekararaj, Alexander E Smith, PhD, Syed A Mian, Pramila Krishnamurthy, Azim M Mohamedali, PhD, Nicholas C Lea, PhD, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, FRCP, FRCPath, Sabine Pomplun, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 792.

https://doi.org/10.1182/blood.V118.21.792.792

Published: 2011

Journal Articles

Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction

Louise M Arnold, RN, BSc, hons, Gemma L Brooksbank, RN, BSc, hons, Richard J Kelly, MBChB, FRCPath, Anita Hill, MBChB, PhD, Stephen John Richards, PhD, FRCPath, Rachel Senior, MPharm, Tracy Downing, Claire McKinley, BSc, James Brown, BMus, Ibrahim Momoh, RN, Modupe Elebute, MBBS, MD, Peter Hillmen, MBChB, PhD

Blood (2011) 118 (21): 4368.

https://doi.org/10.1182/blood.V118.21.4368.4368

Published: 2011

Journal Articles

Reduction of Tregs with Expansion of Th1 Cells and Lack of IFN-γ Secretion by GPI Negative T-Cells In PNH

Shahram Kordasti, MD, PhD, Modupe Elebute, MBBS, MD, MRCP, FRCPath, Pilar Perez Abellan, Austin G Kulasekararaj, Janet Hayden, Azim Mohamedali, PHD, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2010) 116 (21): 2240.

https://doi.org/10.1182/blood.V116.21.2240.2240

Published: 2010

Journal Articles

Low Level Residual Extravascular Haemolysis Is Commom Following Eculizumab Treatment In Paroxysmal Nocturnal Haemoglobinuria(PNH), but Does Not Affect Transfusion Requirement

Austin G Kulasekararaj, PhD, Dupe Odunsi, PhD, Pramila Krishnamurthy, PhD, Hayden Janet, PhD, Ibrahim Momoh, Ghulam J. Mufti, DM, FRCP, FRCPath, Judith C. W. Marsh, MD, Modupe Elebute, MBBS, MD, MRCP, FRCPath

Blood (2010) 116 (21): 4240.

https://doi.org/10.1182/blood.V116.21.4240.4240

Published: 2010

Journal Articles

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Jörg Schubert, MD, Peter Hillmen, MB, PhD, Ulrich Dührsen, DM, Neal S. Young, MD, Modupe Elebute, MB, MD, Jeffrey Szer, MB, BS, Giacomo Gianfaldoni, MD, Gérard Socié, MD, PhD, Paul Browne, MD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Petra Muus, MD, PhD

Blood (2006) 108 (11): 124.

https://doi.org/10.1182/blood.V108.11.124.124

Published: 2006

Journal Articles

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Anita J. Dickinson, MSc, Anita Hill, MD, David Buchanon, MA, Louise Arnold, BSc, Modupe Elebute, MD, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 1047.

https://doi.org/10.1182/blood.V106.11.1047.1047

Published: 2005

NARROW

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,

TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis

Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction

Reduction of Tregs with Expansion of Th1 Cells and Lack of IFN-γ Secretion by GPI Negative T-Cells In PNH

Low Level Residual Extravascular Haemolysis Is Commom Following Eculizumab Treatment In Paroxysmal Nocturnal Haemoglobinuria(PNH), but Does Not Affect Transfusion Requirement

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only